<DOC>
	<DOCNO>NCT01001195</DOCNO>
	<brief_summary>This study evaluate safety , efficacy dose-response AGN-210669 . This study also compare AGN-210669 bimatoprost ophthalmic solution ( LUMIGANÂ® ) .</brief_summary>
	<brief_title>Safety Efficacy Three Formulations AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Ocular hypertension primary openangle glaucoma eye Patient require IOP lower medication eye Ocular hyperemia ocular surface finding either eye Active ocular disease Current anticipate use topical ocular medication ( include artificial tear ) study Intraocular surgery within past six month unilateral cataract surgery . Functionally significant visual field loss Anticipated wear contact lens study Use medication affect IOP glaucoma treat medication , within 2 month screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>